Increased levels of transforming growth factor β receptor type I and up-regulation of matrix gene program: A model of scleroderma

Arthritis and Rheumatism

Volumn 54, Issue 9, 2006, Pages 3011-3021

  Pannu, Jaspreet ^a   Gardner, Humphrey ^b   Shearstone, Jeffrey R ^b   Smith, Edwin ^a   Trojanowska, Maria ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ARTICLE; CLINICAL ARTICLE; COL1A1 GENE; COL1A2 GENE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE ARRAY ANALYSIS; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENETIC ANALYSIS; GENETIC REGULATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SKIN FIBROBLAST; WESTERN BLOTTING;

ACTIVIN RECEPTORS, TYPE I; BLOTTING, NORTHERN; COLLAGEN; DNA PRIMERS; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN;

EID: 33749320619     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22063     Document Type: Article

References (31)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
2. Trojanowska M. Molecular aspects of scleroderma. Front Biosci 2002;7:d608-18.
3. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 2002;227:301-14.
4. Ihn H. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 2005;7:156-62.
5. Strehlow D, Jelaska A, Strehlow K, Korn JH. A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma. J Clin Invest 1999;103:1179-90.
6. Jun JB, Kuechle M, Min J, Shim SC, Kim G, Montenegro V, et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 2005;124:298-303.
7. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-β signaling in cultured scleroderma fibroblasts. Am J Pathol 2005;166:1451-63.
8. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003;163:571-81.
9. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319-24.
10. Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, Trojanowska M, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006;54:1961-73.
11. Pannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 2004;16:739-45.
12. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
13. Kubo M, Ihn H, Yamane K, Tamaki K. Upregulated expression of transforming growth factor-β receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol 2002;29:2558-64.
14. Pannu J, Gore-Hyer E, Yamanaka M, Smith EA, Rubinchik S, Dong JY, et al. An increased transforming growth factor β receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis Rheum 2004;50:1566-77.
15. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48:1964-78.
16. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002;99:3908-13.
17. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004;113:253-64.
18. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
20. Ishikawa O, LeRoy EC, Trojanowska M. Mitogenic effect of transforming growth factor β1 on human fibroblasts involves the induction of platelet-derived growth factor α receptors. J Cell Physiol 1990;145:181-6.
21. Markiewicz M, Smith EA, Rubinchik S, Dong JY, Trojanowska M, LeRoy EC. The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblasts. Clin Exp Rheumatol 2004;22 Suppl 33:S31-4.
22. Denton CP, Lindahl GE, Khan K, Shiwen X, Ong VH, Gaspar NJ, et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRIIΔk). J Biol Chem 2005;280:16053-65.
23. Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblasts. Arthritis Rheum 2004;50:4008-21.
24. LeRoy EC. A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 1992;51:286-8.
25. Gore-Hyer E, Pannu J, Smith EA, Grotendorst G, Trojanowska M. Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. Arthritis Rheum 2003;48:798-806.
26. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000;43:2230-9.
27. Wahab NA, Weston BS, Mason RM. Modulation of the TGFβ/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 2005;307:305-14.
28. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001;44:474-80.
29. Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg S. Expression of TGF-β1, -β2 and -β3 in localized and systemic scleroderma. J Dermatol Sci 1999;21:13-22.
30. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577-84.
31. Moustakas A, Heldin CH. Non-Smad TGF-β signals. J Cell Sci 2005;118:3573-84.